Publications by authors named "R Alikhan"
Article Synopsis
- The REVERXaL study investigates the characteristics and management of hospitalized patients who experience major bleeds related to factor Xa inhibitors (FXai), a new class of anticoagulants.
- It includes two cohorts: a historical cohort analyzing past patient data and a prospective cohort that evaluates current treatment and patient-reported outcomes over three months.
- The study aims to provide valuable information on treatment approaches and patient outcomes, potentially improving clinical practices for managing FXai-associated major bleeds.
A shared decision on the most appropriate agent for the treatment of cancer-associated thrombosis should consider the following factors, which should be reassessed as patients continue along their cancer care pathway: risk of bleeding; tumour site; suitability of oral medications; potential for drug-drug interactions; and patient preference and values regarding choice of drug. Continuing anticoagulation beyond 6 months in patients with cancer-associated venous thromboembolism and active cancer is recommended.
View Article and Find Full Text PDFBackground: In patients with acute venous thromboembolism (VTE), the rates of recurrence and major bleeding are highest during the first weeks of anticoagulation. The CARAVAGGIO trial demonstrated noninferiority of apixaban to dalteparin for treatment of cancer-associated VTE without an increased risk of major bleeding. We compared the early time course of VTE recurrence and major bleeding events of apixaban compared with dalteparin at 7, 30, and 90 days of treatment in patients with cancer-associated VTE.
View Article and Find Full Text PDF